IP Library Granted Patent US 8,846,029
Granted Patent B2
US 8,846,029 · App. 13/540,827 · Granted Sep 30, 2014

Treatment of IBD and IBS using both probiotic bacteria and fermented cereal as treatment effectors

Inventor: Hans Israelsen (Allerod, DK)
Assignee: Nordisk Rebalance A/S
A61K35/66A23V2200/3204A61K35/744A61K36/899A61K35/745A61K35/74A23L1/3014A23V2002/00A61K45/06A61K31/685A61K35/742A61K35/747A23L1/172
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 8,846,029
App. No.
13/540,827
Granted
Sep 30, 2014
Kind
B2
Abstract

The invention covers a novel treatment strategy that considerably improves conventional probiotic treatments of inflammatory bowel diseases, irritable bowel syndrome and other gastrointestinal disorders. Both probiotic microorganisms and the carrier of the probiotic microorganisms in form of a fermented cereal gruel are used as treatment effectors. Phospholipids may also be an effector. The novel treatment strategy is capable of removing the symptoms of inflammatory bowel diseases regardless of a mild, moderate or severe stage of the disease.

Claims (28)

1. A method of treating inflammatory bowel disease (IBD) in the form of ulcerative colitis or Crohn's disease in a human subject, the method comprising administering to the subject a fermented cereal comprising Lactobacillus plantarum cells of strain 299 or 299, wherein the fermented cereal is administered in an amount providing at least 18 g (dry weight) of fermented cereal and at least 1×10 11 cfu of said Lactobacillus plantarum cells on a daily basis, and wherein the fermented cereal is administered for a period of time effective to reduce at least one symptom of IBD.

2. The method of claim 1 , wherein the subject has ulcerative colitis.

3. The method of claim 1 , wherein the subject has Crohn's disease.

4. The method of claim 1 , wherein the treatment induces remission.

5. The method of claim 1 , wherein the treatment provides maintenance of the disease.

6. The method of claim 1 , wherein the cereal is fermented by said Lactobacillus plantarum cells.

7. The method of claim 1 , wherein said Lactobacillus plantarum cells are added to the fermented cereal.

8. The method of claim 1 , where the cereal that is fermented is selected from barley, corn, millet, oats or oatmeal, quinoa, rice, rye, sorghum, triticale, wheat, and cassava.

9. The method of claim 1 , wherein the cereal that is fermented is oats or oatmeal.

10. The method of claim 1 , wherein the fermented cereal is administered to the subject in an effective amount on a daily basis.

11. The method of claim 10 , wherein the fermented cereal is administered in an amount providing at least 2×10 11 cfu of said Lactobacillus plantarum cells on a daily basis.

12. The method of claim 10 , wherein the fermented cereal is administered in an amount providing at least 5×10 11 cfu of said Lactobacillus plantarum cells on a daily basis.

13. The method of claim 10 , wherein the fermented cereal is administered in an amount providing at least 36 g (dry weight) of fermented cereal on a daily basis.

14. The method of claim 10 , wherein the fermented cereal is administered in an amount providing at least 90 g (dry weight) of fermented cereal on a daily basis.

15. The method of claim 1 , wherein the fermented cereal comprises at least 1×10 8 cfu/ml of said Lactobacillus plantarum cells.

16. The method of claim 1 , wherein the fermented cereal comprises at least 1×10 9 cfu/ml of said Lactobacillus plantarum cells.

17. The method of claim 1 , wherein the fermented cereal comprises at least 0.05 g/ml (dry weight) of fermented cereal.

18. The method of claim 1 , wherein the fermented cereal comprises at least 0.1 g/ml (dry weight) fermented cereal.

19. The method of claim 1 , wherein the fermented cereal comprises at least 0.18 g/ml (dry weight) fermented cereal.

20. The method of claim 1 , wherein the fermented cereal comprises added lecithin or added phosphatidylcholine and is orally administered.

21. The method of claim 20 , wherein the fermented cereal is administered in an amount providing at least 0.1 g added lecithin or phosphatidylcholine on a daily basis.

22. The method of claim 20 , wherein the fermented cereal is administered in an amount providing at least 0.5 g added lecithin or phosphatidylcholine on a daily basis.

23. The method of claim 20 , wherein the fermented cereal is administered in an amount providing at least 1 g added lecithin or phosphatidylcholine on a daily basis.

24. The method of claim 1 , wherein the fermented cereal further comprises one or more food additives, medical additives, taste enhancers, food colors, pH or osmosis regulators, vitamins, herbs, herbal components, minerals, viscosity regulators, lipids, emulsifiers, glutamine or other amino acids, antioxidants, blood pressure regulators, or pain relief substances.

25. The method of claim 1 , wherein the fermented cereal further comprises an additional active agent suitable for treatment of gastrointestinal disorders.

26. The method of claim 1 , wherein the fermented cereal is administered in the form of a drinkable, eatable, anally administrable, or tube administrable product.

27. The method of claim 1 , wherein the fermented cereal comprises fermented oats, lactic acid bacteria, and added lecithin or phosphatidylcholine and is orally administered.

28. The method of claim 1 , wherein said symptom of IBD is selected from the group consisting of abdominal pain, diarrhea, bloody stool, increased number of daily stools, deficiency of intestinal mucus, loss of weight, and tiredness.

Assignments (2)
CHANGE OF NAME Recorded Aug 24, 2018
From: NORDISK REBALANCE A/S
To: NORDIC REBALANCE A/S
Reel/Frame 046943/0935 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jun 22, 2017
From: ISRAELSEN, HANS
To: NORDISK REBALANCE A/S
Reel/Frame 042790/0411 →
Priority Claims (2)
EP 05388079 · Sep 28, 2005 · regional
DK 2006 00529 · Apr 12, 2006 · national
Continuity (4)
Division 12066246
Provisional Application 60744717 · Apr 12, 2006
Provisional Application 60721276 · Sep 28, 2005
Related Publication 20120269791A1 · Oct 25, 2012